Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

KA Marr, RA Carter, F Crippa, A Wald… - Clinical Infectious …, 2002 - academic.oup.com
Reports have focused on the emergence of moulds as pathogens in recipients of
hematopoietic stem cell transplants. To review the incidence of and risks for mould …

Nanoparticle–cell interaction: a cell mechanics perspective

D Septiadi, F Crippa, TL Moore… - Advanced …, 2018 - Wiley Online Library
Progress in the field of nanoparticles has enabled the rapid development of multiple
products and technologies; however, some nanoparticles can pose both a threat to the …

[PDF][PDF] Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus …

…, AM Pagnoni, V Bonfante, R Musumeci, F Crippa - J Clin …, 1987 - researchgate.net
VER THE PAST two decades, treatment of Hodgkin's disease has evolved considerably
through innovations in the management of various stages."-3 The impact of various …

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non …

…, Z Magnani, SK Perna, V Valtolina, F Crippa… - The lancet …, 2009 - thelancet.com
Background Procedures to prevent severe graft-versus-host disease (GVHD) delay immune
reconstitution secondary to transplants of haploidentical haemopoietic stem cells for the …

Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants

KA Marr, F Crippa, W Leisenring, M Hoyle, M Boeckh… - Blood, 2004 - ashpublications.org
Prophylactic fluconazole prevents candidiasis; however, this drug has no activity against
molds. We performed a randomized trial to determine whether prophylactic itraconazole …

Imatinib mesylate in chordoma

…, A Messina, S Stacchiotti, E Tamborini, F Crippa… - Cancer, 2004 - Wiley Online Library
BACKGROUND To the authors' knowledge, no effective medical therapy currently is
available for advanced chordoma. Imatinib mesylate is a tyrosine kinase inhibitor targeting …

Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study

LD Locati, P Bossi, F Perrone, P Potepan, F Crippa… - Oral oncology, 2009 - Elsevier
EGFR overexpression in salivary gland carcinomas provides the rational for the
investigation of anti-EGFR treatments in recurrent and/or metastatic salivary gland cancers …

[HTML][HTML] Staging and follow-up of high-grade malignant salivary gland tumours: The role of traditional versus functional imaging approaches–A review

N Freling, F Crippa, R Maroldi - Oral oncology, 2016 - Elsevier
Following up on the Consensus Conference on high-grade malignant salivary gland
tumours (HGMSGT) in adult patients in Brescia, Italia, in October 2014, we review the current …

Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 …

C Chiesa, V De Sanctis, F Crippa, M Schiavini… - European journal of …, 1997 - Springer
The aim of this study was to determine the non-extremity gamma dose received by a
technician while performing an ordinary nuclear medicine procedure or a static (ie without …

[HTML][HTML] Response to imatinib plus sirolimus in advanced chordoma

…, E Palassini, E Virdis, A Messina, F Crippa… - Annals of …, 2009 - Elsevier
Background Imatinib (IM) is active in advanced chordoma. The evidence of upstream and/or
downstream mammalian target of rapamycin (mTOR) pathway activation prompted us to …